Arrowhead Pharmaceuticals Inc. (ARWR) is a multinational biopharmaceutical company based in Pasadena, California. Its primary focus is on developing medicines that can ideally treat intractable diseases by silencing the genes responsible for them. Known for their pioneering spirit and innovative solutions, ARWR's mission is to fight severe and genetically determined diseases at the molecular level, offering hope to millions of patients worldwide.
The company is at the forefront of the scientific world, working diligently to develop RNA interference (RNAi) therapeutics. RNAi is a natural process that cells use to turn off genes and an approach that has the potential to create therapies for diseases that are hard to treat using traditional methods. By using this innovative technological strategy, ARWR's products have the potential to provide effective, new and innovative solutions to individuals suffering from debilitating chronic illnesses or genetically correlated diseases.
Arrowhead is relentlessly striving to become a pioneer in RNAi-based therapeutics, maintaining a deep pipeline of “RNAi” drugs for a range of diseases including liver diseases, cardiovascular diseases, respiratory conditions, and chronic hepatitis B infections. Some of its leading products include ARO-AAT, designed to treat liver disease associated with alpha-1 antitrypsin deficiency, and ARO-APOC3, a treatment for hypertriglyceridemia.
ARWR has several partnerships with industry leaders to help speed their therapies to the market by leveraging their expertise in RNAi delivery and drug development. For instance, Arrowhead teamed up with Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, to work on their ARO-HBV drug, which is designed to treat chronic hepatitis B.
Since its establishment, Arrowhead Pharmaceuticals has adopted an innovative pharmaceutical development strategy, consistently demonstrating its progressive attitude towards cutting-edge research to combat genetically linked diseases. This strategy has led to its transformation into a highly reputable institution in the biotechnology industry. The company’s continued commitment to innovation and its targeted approach to tackling complex genetic disorders make it a valuable contributor to global medical advancements.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Shares of Arrowhead Pharmaceuticals (ARWR) experienced their worst day in over a year, falling more than 10% despite releasing positive early-stage human trial data for its experimental cholesterol drug, ARO-DIMER-PA. The drug showed significant reductions in "bad" cholesterol and triglycerides, but analysts suggest the selloff could be a "sell the news" reaction, as the stock had previously run up in anticipation of the catalyst. Retail investors, however, appear to be buying the dip, with sentiment shifting from bearish to bullish on platforms like Stocktwits.
A director at Arrowhead Pharmaceuticals, Michael S. Perry, sold 11,600 shares of common stock for $1 million on August 18, 2026. This sale represents 9% of his direct holdings, but he remains a significant stakeholder. Despite the sale, analysts are bullish on the stock, with a median one-year price target indicating a 26.8% gain.
Arrowhead Pharmaceuticals (ARWR) presented Phase 3 results for plozasiran, showing a 78% reduction in pancreatitis events for severe hypertriglyceridemia patients, with a 4.1% absolute risk reduction across the broad population. While the benefit for patients with a history of pancreatitis was substantially higher (34% absolute risk reduction), the overall benefit and metabolic safety require careful consideration. The company plans to submit a supplemental New Drug Application for a broader label.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced its participation in three investor conferences in September 2026: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. The company will present in fireside chats at each event, with presentation materials available on its investor relations website. Arrowhead is a commercial-stage pharmaceutical company focused on developing RNAi therapeutics for intractable diseases.
Arrowhead Pharmaceuticals' plozasiran (Redemplo) for severe hypertriglyceridemia has received mixed reactions from analysts despite showing "placebo-like safety" in late-stage studies. While Stifel views plozasiran's safety and quarterly dosing as potential differentiators against Ionis Pharmaceuticals' monthly injectable Tryngolza, BMO Capital Markets points to concerns about plozasiran worsening glycemic control in diabetic patients. Both firms agree that the market is large enough for multiple significant products, with Arrowhead planning an FDA submission this year.
An independent director at Arrowhead Pharmaceuticals recently sold US$1.0 million worth of stock, reducing their holding by 10%. Over the last year, the Chairman also sold US$12 million in shares at a price below the current market value. These transactions indicate a lack of insider buying over the past year, despite significant insider ownership in the company.
Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with 62.61% of the stock held by such investors. Despite missing analyst EPS estimates for the last quarter, Arrowhead Pharmaceuticals saw a 171% year-over-year revenue increase and maintains a "Moderate Buy" consensus rating from analysts with a target price of $97.33.